Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Debt (2023 - 2025)

Historic Total Debt for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $10.1 million.

  • BioLineRx's Total Debt fell 6375.34% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 6375.34%. This contributed to the annual value of $13.4 million for FY2024, which is 3749.1% up from last year.
  • As of Q3 2025, BioLineRx's Total Debt stood at $10.1 million, which was down 6375.34% from $11.2 million recorded in Q2 2025.
  • BioLineRx's Total Debt's 5-year high stood at $29.4 million during Q2 2024, with a 5-year trough of $9.6 million in Q1 2024.
  • In the last 3 years, BioLineRx's Total Debt had a median value of $11.5 million in 2023 and averaged $14.3 million.
  • As far as peak fluctuations go, BioLineRx's Total Debt surged by 15443.71% in 2024, and later crashed by 6375.34% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Total Debt stood at $9.8 million in 2023, then soared by 37.49% to $13.4 million in 2024, then decreased by 25.0% to $10.1 million in 2025.
  • Its Total Debt stands at $10.1 million for Q3 2025, versus $11.2 million for Q2 2025 and $12.3 million for Q1 2025.